高级检索
当前位置: 首页 > 详情页

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

文献详情

资源类型:
WOS体系:
机构: [1]Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China [2]Chinese Acad Med Sci, Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing, Peoples R China
出处:
ISSN:

关键词: OPTICAL COHERENCE TOMOGRAPHY MACULAR DETACHMENT THICKNESS RANIBIZUMAB CYTOKINES EDEMA

摘要:
Purpose To evaluate choroid thickness and macular retinal metrics in treatment naive retinal vein occlusion (RVO) patients with serous retinal detachment (SRD) before and after intravitreal anti-vascular endothelial cell growth factor (VEGF) injection and to elucidate the possible role of choroid in the development of SRD and the potential role of SRD as a prognostic parameter. Methods This is a retrospective study involving 85 RVO patients, 41 central retinal vein occlusion (CRVO), and 44 branch retinal vein occlusion (BRVO), with macular edema: 21 central retinal vein occlusion and 22 branch retinal vein occlusion with SRD and the rest without SRD. Patients were evaluated with ophthalmic examinations and swept-source optical coherence tomography (SS-OCT) both before and 4-6 weeks after intravitreal anti-VEGF treatment. Choroid thickness and retinal metrics were measured and compared between SRD and non-SRD groups within each RVO subtype. Results In both CRVO and BRVO patients, the mean central subfield foveal thickness (CSFT) and central subfoveal choroid thickness (CSCT) of the SRD groups were thicker than those in the non-SRD groups (p < 0.05) at onset. After one anti-VEGF injection, CSFT and FNRT decreased in all groups (p < 0.05). The CSCTs were thicker in the SRD groups compared with the non-SRD groups (p < 0.05). The mean changes of CSFT were more remarkable in the SRD groups (p < 0.05). Conclusion Thicker choroid was a feature of naive RVO patients with SRD and SRD may be an indicator of better anatomical recovery of retina in RVO patients after a single dose of anti-VEGF treatment.

基金:

基金编号: 2018PT32029

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 3 区 眼科学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 眼科学
第一作者:
第一作者机构: [1]Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China [2]Chinese Acad Med Sci, Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing, Peoples R China
通讯作者:
通讯机构: [1]Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China [*1]Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China [2]Chinese Acad Med Sci, Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing, Peoples R China [*2]Chinese Acad Med Sci, Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)